ReviewNuclear medicine and molecular imaging2017
Review in Nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies.Molecular biomedicine · 2026Review
- Nanodynamic therapy for cancer: mechanistic innovations, targeting strategies and multimodal treatments.Journal of translational medicine · 2025Review
- Innovative applications and research advances of bacterial biosensors in medicine.Frontiers in microbiology · 2025Review
- Recent advances in gut microbiota-based nanotherapies for cancer treatment.Frontiers in pharmacology · 2025Review
- Enhanced anti-cancer efficacy of arginine deaminase expressed by tumor-seeking Salmonella Gallinarum.Oncogene · 2024Article
- Enhanced bacterial cancer therapy delivering therapeutic RNA interference of c-Myc.Cell & bioscience · 2024Article
- IntegratedNAR genomics and bioinformatics · 2023Article
- Pancreatic Cancer Resistance to Treatment: The Role of Microbiota.Biomedicines · 2023Review
- Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles.Frontiers in bioengineering and biotechnology · 2023Review
- Review
- Downregulation of AKT/mTOR signaling pathway forJournal of Cancer · 2022Article
- Coating bacteria for anti-tumor therapy.Frontiers in bioengineering and biotechnology · 2022Review
- Pattern of F-18 FDG Uptake in Colon Cancer after Bacterial Cancer Therapy Using EngineeredMolecular imaging · 2022Article
- Article
- Tumor Temporal Proteome Profiling Reveals the Immunological Triple Offensive Induced by Synthetic Anti-CancerFrontiers in immunology · 2021Article
- Attenuated Salmonella engineered with an apoptosis-inducing factor (AIF) eukaryotic expressing system enhances its anti-tumor effect in melanoma in vitro and in vivo.Applied microbiology and biotechnology · 2020Article
- Development of Oxytolerant Salmonella typhimurium Using Radiation Mutation Technology (RMT) for Cancer Therapy.Scientific reports · 2020Article
- Dual Role of Bacteria in Carcinoma: Stimulation and Inhibition.International journal of microbiology · 2020Review
- Secreting-lux/pT-ClyA engineered bacteria suppresses tumor growth via interleukin-1β in two pathways.AMB Express · 2019Article
- Targeting ProgrammedCancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of bacteria for cancer therapy, which was proposed many years ago, was not recognized as a potential therapeutic strategy until recently. Technological advances and updated knowledge have enabled the genetic engineering of bacteria for their safe and effective application in the treatment of cancer. The efficacy of radiotherapy depends mainly on tissue oxygen levels, and low oxygen concentrations in necrotic and hypoxic regions are a common cause of treatment failure. In addition, the distribution of a drug is important for the therapeutic effect of chemotherapy, and the poor vasculature in tumors impairs drug delivery, limiting the efficacy of a drug, especially in necrotic and hypoxic regions. Bacteria-mediated cancer therapy (BMCT) relies on facultative anaerobes that can survive in well or poorly oxygenated regions, and it therefore improves the therapeutic efficacy drug distribution throughout the tumor mass. Since the mid-1990s, the number of published bacterial therapy papers has increased rapidly, with a doubling time of 2.5 years in which the use of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.